Traws Pharma
TRAW
18 hedge funds and large institutions have $4.29M invested in Traws Pharma in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 9 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
89% more capital invested
Capital invested by funds: $2.27M → $4.29M (+$2.02M)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
6% more funds holding
Funds holding: 17 → 18 (+1)
0.28% more ownership
Funds ownership: 0.09% → 0.36% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.96M |
| 2 |
BlackRock
New York
|
+$428K |
| 3 |
Renaissance Technologies
New York
|
+$299K |
| 4 |
HWA
Hillcrest Wealth Advisors
Hazlet,
New Jersey
|
+$125K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
+$94.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
-$524K |
| 2 |
6CM
683 Capital Management
New York
|
-$476K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$205K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$95K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22K |
TRAW Hedge Fund Activity: Q4 2019 in Review
18 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2019, worth a combined $4.29M — up 89% from $2.27M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TRAW positions and 9 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, adding an estimated $3.96M. The largest seller was Tyndall Capital Partners, exiting entirely with an estimated $524K sold.
- 18 institutional investors held Traws Pharma (TRAW) as of Q4 2019, up from 17 in Q3 2019.
- Funds reported $4.29M of Traws Pharma stock for Q4 2019, up 89% quarter-over-quarter.
- 10 funds opened new Traws Pharma positions in Q4 2019 and 9 closed out, a net change of +1 holder.
- The largest Traws Pharma buyer in Q4 2019 was Sabby Management, an estimated $3.96M added.
- The largest Traws Pharma seller in Q4 2019 was Tyndall Capital Partners, an estimated $524K sold.
Based on aggregated 13F filings for Q4 2019.